HemoSonics specializes in advanced hemostasis testing technologies, particularly through its flagship product, the Quantra® Hemostasis System. This system is FDA-approved for use in various critical medical settings, including cardiac surgery, trauma, liver transplantation, and major orthopedic surgeries. The Quantra system employs proprietary ultrasound technology known as Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry, which allows for the direct measurement of viscoelastic properties in whole blood samples. This innovative approach provides rapid, actionable results that can significantly reduce unnecessary blood product usage, hospital stays, and complications related to bleeding or transfusions. The system is designed for ease of use, requiring minimal training for healthcare providers, and offers a compact, automated solution that integrates seamlessly into existing healthcare IT infrastructures.

In addition to the Quantra system, HemoSonics has introduced the qLabs® FIB Fibrinogen Monitoring System, which measures fibrinogen levels quickly at the point of care. This device is crucial for managing critical bleeding situations, as fibrinogen is often the first coagulation factor to drop during active bleeding. The qLabs system provides results within 1 to 10 minutes, enabling timely and targeted therapeutic interventions. Together, these technologies represent a significant advancement in the field of hemostasis testing, enhancing the ability of healthcare providers to make informed decisions in acute care settings and ultimately improving patient outcomes.

United States

HemoSonics is breaking new ground in point-of-care Viscoelastic #hemostasis testing. When time is critical, the Quantra® QPlus® System offers rapid, accurate, and easy to understand results that enable clinicians to make more informed #transfusion decisions, more quickly. This novel, cartridge-based POC VET system now has De Novo marketing authorization in the USA and is intended to assess the coagulation status of perioperative patients at the point of care. 

Follow us at @HemoSonics

HemoSonics

Company Details